InflaRx (IFRX) Change in Receivables (2024)

InflaRx (IFRX) posted Change in Receivables of -$70114.7 for Q3 2024, down 665.42% sequentially from $12400.4 in Q2 2024.

InflaRx (IFRX) Change in Receivables (2024) Analysis & Trends

InflaRx has reported Change in Receivables for 1 years, with the latest figure at -$70114.7 in Q3 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Change in Receivables (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	140.20 Mn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	838.50 Mn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-53.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	117.58 Mn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	31.60 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	94.29 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	37.16 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	-
10	InflaRx	140.30 Mn	-43.96 Mn	2.74 Bn	1.15 Mn

Download Data